StreetInsider.com News Articles

Form 4 NeuroPace Inc For: Aug 27 Filed by: Becker Joel

Fri, 28 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26998949.html

Form 4 NeuroPace Inc For: Aug 27 Filed by: Becker Joel

Fri, 28 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26998949.html

Form 4 NeuroPace Inc For: Aug 27 Filed by: Morrell Martha

Fri, 28 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260828/26998937.html

Form 4 NeuroPace Inc For: Aug 27 Filed by: Morrell Martha

Fri, 28 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260828/26998937.html

NeuroPace (NPCE) Reiterated at Overweight by Cantor Fitzgerald on Commercial Momentum

Mon, 17 Aug 2026 07:57:27 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $21.00 price target on NeuroPace Inc (NASDAQ: NPCE).

The analyst commented, "We remain encouraged by NPCE’s commercial momentum & product pipeline despite IGE timing uncertainty. ECoG Assistant launched in 2Q26 to improve clinician efficiency & drive RNS adoption, while NPCE’s >27M intracranial EEG recordings support its expanding AI platform. Remote care remains on track for FDA submission by YE26, while management targets cash flow breakeven exiting 2027 without sacrificing investment in adult focal & IGE growth. Management also feels good about the direction of the 2027 OPPS proposal and will continue

Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26933020.html

Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC

Fri, 14 Aug 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26933020.html

NeuroPace (NPCE) Tops Q2 EPS by 3c

Tue, 11 Aug 2026 17:08:19 -0400

NeuroPace (NASDAQ: NPCE) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $22.83 million versus the consensus estimate of $22.56 million.

For earnings history and earnings-related data on NeuroPace (NPCE) click here.

Form 10-Q NeuroPace Inc For: Jun 30

Tue, 11 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260811/26906420.html

Form 10-Q NeuroPace Inc For: Jun 30

Tue, 11 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260811/26906420.html

Form 8-K NeuroPace Inc For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905702.html

Form 8-K NeuroPace Inc For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905702.html

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Tue, 11 Aug 2026 16:05:00 -0400

--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--

--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS® revenue from existing indications--

--Preparation remains on track for SIR meeting with FDA regarding the IGE PMA supplement, supported by 24-month NAUTILUS data showing a 100% median reduction in GTC seizures among evaluable patients1--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Tue, 11 Aug 2026 16:05:00 -0400

--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--

--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS® revenue from existing indications--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Tue, 11 Aug 2026 16:05:00 -0400

--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--

--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS® revenue from existing indications--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Tue, 11 Aug 2026 16:05:00 -0400

--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--

--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS® revenue from existing indications--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial

H.C. Wainwright Reiterates Buy Rating on NeuroPace Inc (NPCE)

Wed, 29 Jul 2026 06:53:30 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $20.00 price target on NeuroPace Inc (NASDAQ: NPCE).

The analyst commented: "Yesterday, NeuroPace announced that the company’s Premarket Approval Supplement (PMA-S) seeking to expand the RNS System labeled indication into drug-resistant idiopathic generalized epilepsy (IGE) was not approvable in its current form, as indicated by the FDA. While this is a disappointing outcome, it is encouraging that the FDA did not issue a denial or request an additional clinical trial. The agency did request additional clinical evidence from the NAUTILUS trial and literature supporting the submission. We do not find that

Form 8-K NeuroPace Inc For: Jul 28

Tue, 28 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260728/26827670.html

Form 8-K NeuroPace Inc For: Jul 28

Tue, 28 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260728/26827670.html

FDA declines to approve NeuroPace's RNS expansion for epilepsy

Tue, 28 Jul 2026 16:01:44 -0400

NeuroPace, Inc. (Nasdaq: NPCE) said the U.S. Food and Drug Administration has determined that its Premarket Approval supplement seeking to expand the labeled indication for its RNS System to treat antiseizure medication-resistant idiopathic generalized epilepsy (IGE) is not approvable in its current form.

The FDA has requested additional clinical evidence from NeuroPace's NAUTILUS trial and supporting literature. Following meetings with the agency, NeuroPace said it plans to file a Submission Issue Request and intends to amend its submission with supplemental data, including additional information about the patient populations evaluated in the NAUTILUS trial.

"While we are disappointed with not receiving an initial

FDA declines to approve NeuroPace's RNS expansion for epilepsy

Tue, 28 Jul 2026 16:01:44 -0400

"While we are disappointed with not receiving an initial

FDA declines to approve NeuroPace's RNS expansion for epilepsy

Tue, 28 Jul 2026 16:01:44 -0400

"While we are disappointed with not receiving an initial

FDA declines to approve NeuroPace's RNS expansion for epilepsy

Tue, 28 Jul 2026 16:01:44 -0400

"While we are disappointed with not receiving an initial

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Tue, 28 Jul 2026 16:01:00 -0400

-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and literature supporting the submission has been requested --

-- FDA has invited continued dialogue, and NeuroPace will be submitting a Submission Issue Request and intends to continue working with FDA on a path for approval of the submission --

-- Management will host a conference call to discuss this communication from the FDA at 4:30pm E.T./1:30pm P.T. --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq:

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Tue, 28 Jul 2026 16:01:00 -0400

-- FDA has invited continued dialogue, and NeuroPace will be submitting a Submission Issue Request and intends to continue working with FDA on a path for approval of the submission --

-- Management will host a conference call to discuss this communication from the FDA at 4:30pm E.T./1:30pm P.T. --

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: